CJC-1295 No DAC & Ipamorelin: Research Application Comparison
CJC-1295 No DAC GHRH receptor agonist ~30 minutes Increases GH pulse amplitude High (targets GHRH receptors specifically) 100–200 mcg per dose Amplifying endogenous GH secretory events without sustained elevation Ipamorelin Ghrelin receptor agonist (GHSR-1a) ~
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- GHRH receptor agonist
- ~30 minutes
- Increases GH pulse amplitude
- High (targets GHRH receptors specifically)
- 100–200 mcg per dose
- Amplifying endogenous GH secretory events without sustained elevation
- Ipamorelin
- Ghrelin receptor agonist (GHSR-1a)
- ~2 hours
- Increases GH pulse frequency and amplitude
- Very high (minimal cortisol/prolactin effect)
- 200–300 mcg per dose
- Selective GH stimulation without metabolic side effects seen in older secretagogues
- Combined Protocol
- Dual receptor activation (GHRH + ghrelin pathways)
- Pulsatile (peaks at 20–30 min)
- Synergistic GH release (2–3× single peptide effect)
- Maintained (both peptides are selective)
- 100–200 mcg CJC / 200–300 mcg Ipa
- Body recomposition research requiring maximal GH stimulation with minimal off-target hormonal disruption
- CJC-1295 With DAC
- GHRH receptor agonist (extended-release)
- 6–8 days
- Sustained GH elevation
- High
- 2 mg weekly (single dose)
- Protocols prioritising convenience over pulsatile rhythm. Produces blunted but prolonged GH increase
- GHRP-6
- Ghrelin receptor agonist (non-selective)
- GH release + cortisol + prolactin elevation
- Low (broad receptor activation)
- Early secretagogue research. Now largely replaced by Ipamorelin due to side effect profile
- Professional Assessment
- CJC-1295 no DAC + Ipamorelin is the current gold standard for fat loss and body recomposition research. The combination produces the highest GH pulse amplitude with the fewest off-target hormonal effects. Older peptides like GHRP-6 or extended-release CJC with DAC are superseded by this protocol in almost every research context.